Insights | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Webinar | February 24, 2021

Protecting Your Trade Secrets from Misappropriation

IP Law Essentials | August 12, 2020

How Biosimilars Are Approved and Litigated: Patent Dance Timeline

Blog | July 10, 2020

Chief Judge Stark Dismisses Hatch-Waxman Case after Paragraph IV to Paragraph III Conversion

Blog | June 22, 2020

FDA Seeks to Modernize the Orange Book

IP Law Essentials | June 04, 2020

Introduction to Biologics and Biosimilars

IP Law Essentials | May 21, 2020

Overview of Approaches to Compulsory Licensing

IP Law Essentials | May 01, 2020

Where Do Juries Come From?

Blog | April 20, 2020

A Biosimilar's Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider

Blog | March 20, 2020

Insulin and Other Biological Products Previously Regulated as "Drugs" Transition to Biologics Regulation on March 23, 2020

Blog | February 07, 2020

Increasing Competition in the Biologic Market Through Truthful Advertising